Slingshot members are tracking this event:

PDUFA for Keytruda(pembrolizumab) in treating patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have already received two or more lines of chemotherapy date set for Sept. 22, 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
MRK Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Biologics License Application, Keytruda, Pembrolizumab